Contingency Management to Promote Smoking Cessation Study
Key facts
- Who runs it
- University of Kansas Medical Center
- Where
- Kansas City, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- People taking part
- 40 people, planned
- Started
- 6 Nov 2026
- Expected to end
- 30 May 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Health Rewards
- Control
- Record updated
- 27 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Smoked in the past 30 days
- Smoke at least 1 cigarette per day when they smoke
- ≥ 18 years old
- Kansas resident
- Speak/read English
- Access to a mobile phone
- Mobile phone receives text messages
- No varenicline contraindications (no acute renal impairment)
- Have no significant co-morbidity (i.e., life-threatening illness, communication barriers or altered mental status)
- Cognitively able to participate
- Physically able to participate
- Not pregnant/breastfeeding
Who cannot take part
- Patient on smoking cessation medication within 2 weeks of admission date
- Medically ineligible for varenicline
- Patient already talked to quitline in the past 2 weeks
- Patients participating in other quit smoking program or research study
Where in United States
- University of Kansas Medical CenterKansas City, United StatesContact: Erica CruvinelNot yet recruiting
About the trial
What the trial wants to find out
Adherence to medication and counseling are strong predictors of smoking cessation success. To provide these two components of care, healthcare providers typically provide people who smoke with prescriptions for cessation medications, and refer them to state-sponsored tobacco quitlines. However, most people who smoke that are referred to quitlines never actually enroll, and those who do enroll participate in very few sessions. Similarly, most people who smoke that receive prescriptions for cessation medications rarely fill or use them, even when they have no co-pay or pre-authorization requirements. To address this problem, the investigators will recruit 40 patients for a pilot 2-arm effectiveness trial. Investigators will recruit patients from the University of Kansas Medical Center. Participants will then be randomized either to control or Health Reward. All participants will receive 12 weeks of varenicline and referrals to their state tobacco quitline (Control condition). In Health rewards arm, participants will additionally receive CM for medication (MedCM) and for counseling (CounsCM). The use of medication will be tracked using an electronic pill dispenser (Wisepill). All participants will be contacted for follow up 3, 6 and 12 weeks after starting the treatment. Feasibility data will include recruitment and retention rates. Preliminary effectiveness outcomes will include treatment engagement and cessation rates.
The 2 groups in the trial
- CounsCM+MedCMTreatment being tested
Mobile Contingency management for counseling attendance (CounsCM) and medication intake (MedCM)
Treatment: Health Rewards
- ControlExisting treatment, for comparison
12 weeks of varenicline and referral to state quitline
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Contingency Management to Promote Smoking Cessation: A Pilot Randomized Clinical Trial
- Record updated
- 27 October 2026